Ignite Creation Date:
2024-05-05 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 9:57 AM
Study NCT ID:
NCT00783198
Status:
COMPLETED
Last Update Posted:
2017-03-03
First Post:
2008-10-30
Brief Title:
Efficacy and Long-Term Safety of Ragweed Ambrosia Artemisiifolia Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma Study P05233COMPLETED
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
A Multicenter Double-Blind Randomized Placebo-Controlled Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed Ambrosia Artemisiifolia Sublingual Tablet SCH 39641 in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the efficacy and safety of ragweed sublingual tablet SCH 39641MK-3641 compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period It is expected that ragweed allergic participants on one of the active arms of the trial will have decreased allergic rhinoconjunctivitis symptoms and require less allergy rescue medications during ragweed pollen season
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-3641-002 | OTHER | Merck Protocol Number | None |
| 2008-003863-38 | EUDRACT_NUMBER | None | None |